Eikon Therapeutics, Inc. EIKN
6.67 USD +0.54 (+8.81%)
At closeNov 11, 2026, 5:35 PM EST
6.66 -0.01 -0.15%
After hours · Nov 11, 5:35 PM ET
6.08 Day range 6.81
5.01 52-week range 17.40
- YTD
- -55.53%
- 1 year
- -55.53%
- Market cap
- 361.28M
- EPS (ttm)
- -8.51
- YTD return
- -55.53%
- 1-year return
- -55.53%
- Volume
- 439.99K
- Avg volume
- 577.25K
- Open
- 6.08
- Previous close
- 6.13
- Day's range
- 6.08 – 6.81
- 52-week range
- 5.01 – 17.40
No chart data for this range yet.
Financials — quick view
EIKN Revenue — quarterly 0
EIKN Net income — quarterly -88.41M
EIKN EPS — quarterly -1.63
News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Eikon Therapeutics Eyes 2027 Melanoma Trial Update, With Key Cancer Data Expected in 2029 
Eikon Therapeutics, Inc. (EIKN) Presents at JP Morgan Biotech Call Series Transcript 
Eikon Therapeutics to Participate in Multiple Investor Conferences in November 
Eikon Therapeutics Announces EIK1001 Plus Pembrolizumab And Chemotherapy In First-Line, Stage 4 Non-Small Cell Lung Cancer Demonstrates Durable Effect In Combination With Standard-Of-Care, With Tolerability Profile Supportive Of Systemic Administration In An Outpatient Setting 
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress 
Eikon Therapeutics Presents Initial And Updated Data For EIK1003 And Initial Data For EIK1004 And EIK1005 At ESMO 2026; Initial And Updated Cohort Data From Ongoing Phase 1/2 Study Of EIK1003 Continue To Support Potentially Differentiated Profile 
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress 
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress 
HC Wainwright & Co. Initiates Coverage On Eikon Therapeutics with Buy Rating, Announces Price Target of $23
Your note
Sign in to keep a note on EIKN — it syncs with the Stock Master app.